Efficacy of clarithromycin on biofilm formationof methicillin-resistant Staphylococcus pseudintermedius

BMC Veterinary Research

J Scott Weese²  Ameet Singh¹  Suresh Neethirajan³  Matthew DiCicco³ 

[1] Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Ontario, Canada;Department of Pathobiology, Ontario Veterinary College, University of Guelph, Ontario, Canada;School of Engineering, University of Guelph, Ontario, Canada

关键词: Macrolide, Clarithromycin;    Biofilm;    Bacteria;    Therapeutic;    Methicillin-resistant;    S. pseudintermedius;    MRSP;   

Others  :  1119662
DOI  :  10.1186/1746-6148-8-225

 received in 2012-06-29, accepted in 2012-11-07,  发布年份 2012

【 授权许可】

   
2012 DiCicco et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Weese JS: A review of multidrug resistant surgical site infections. Vet Comp Orthop Traumatol 2008, 21(1):1-7.
• [2]Vasseur PB, Levy J, Dowd E, Eliot J: Surgical wound infection rates in dogs and cats data from a teaching hospital. Vet Surg 1988, 17(2):60-64.
• [3]Nicholson M, Beal M, Shofer F, Brown DC: Epidemiologic evaluation of postoperative wound infection in clean-contaminated wounds: a retrospective study of 239 dogs and cats. Vet Surg 2002, 31(6):577-581.
• [4]Eugster S, Schawalder P, Gaschen F, Boerlin P: A prospective study of postoperative surgical site infections in dogs and cats. Vet Surg 2004, 33(5):542-550.
• [5]Abraham JL, Morris DO, Griffeth GC, Shofer FS, Rankin SC: Surveillance of healthy cats and cats with inflammatory skin disease for colonization of the skin by methicillin-resistant coagulase-positive staphylococci and Staphylococcus schleiferi ssp. schleiferi. Vet Dermatol 2007, 18(4):252-259.
• [6]Griffeth GC, Morris DO, Abraham JL, Shofer FS, Rankin SC: Screening for skin carriage of methicillin-resistant coagulase-positive staphylococci and Staphylococcus schleiferi in dogs with healthy and inflamed skin. Vet Dermatol 2008, 19(3):142-149.
• [7]Stefani S, Varaldo PE: Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect 2003, 9(12):1179-1186.
• [8]Gortel K, Campbell KL, Kakoma I, Whittem T, Schaeffer DJ, Weisiger RM: Methicillin resistance among staphylococci isolated from dogs. Am J Vet Res 1999, 60(12):1526-1530.
• [9]Vengust M, Anderson ME, Rousseau J, Weese JS: Methicillin-resistant staphylococcal colonization in clinically normal dogs and horses in the community. Lett Appl Microbiol 2006, 43(6):602-606.
• [10]Weese JS: A review of post-operative infections in veterinary orthopaedic sugery. Vet Comp Orthop Traumatol 2008, 21:99-105.
• [11]Chrobak D, Kizerwetter-Swida M, Rzewuska M, Moodley A, Guardabassi L, Binek M: Molecular characterization of Staphylococcus pseudintermedius strains isolated from clinical samples of animal origin. Folia Microbiol (Praha) 2011, 56(5):415-422.
• [12]Turk R, Singh A, Weese JS: Post-hospital discharge procedure specific surgical site infection surveillance in small animal patients, 2nd ASM/ESCMID conference on methicillin-resistant staphylococci in animals: veterinary and public health implications. Washington DC, USA; 2011.
• [13]Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ: Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 2010, 54(10):4329-4334.
• [14]Jefferson KK: What drives bacteria to produce a biofilm? FEMS Microbiol Lett 2004, 236(2):163-173.
• [15]Cohn LA, Middleton JR: A veterinary perspective on methicillin-resistant staphylococci. J Vet Emerg Crit Care (San Antonio) 2010, 20(1):31-45.
• [16]Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A: The calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999, 37(6):1771-1776.
• [17]Osland AM, Vestby LK, Fanuelsen H, Slettemeas JS, Sunde M: Clonal diversity and biofilm-forming ability of methicillin-resistant Staphylococcus pseudintermedius. J Antimicrob Chemother 2012, 67(4):841-848.
• [18]Weese JS, van Duijkeren E: Methicillin-resistant staphylococcus aureus and staphylococcus pseudintermedius in veterinary medicine. Vet Microbiol 2010, 140(3–4):418-429.
• [19]Costerton JW: Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop Relat Res 2005, 437(437):7-11.
• [20]Parra-Ruiz J, Vidaillac C, Rybak MJ: Macrolides and staphylococcal biofilms. Rev Esp Quimioter 2012, 25(1):10-16.
• [21]Sano M, Hirose T, Nishimura M, Takahashi S, Matsukawa M, Tsukamoto T: Inhibitory action of clarithromycin on glycocalyx produced by MRSA. J Infect Chemother 1999, 5(1):10-15.
• [22]Fujimura S, Sato T, Mikami T, Kikuchi T, Gomi K, Watanabe A: Combined efficacy of clarithromycin plus cefazolin or vancomycin against Staphylococcus aureus biofilms formed on titanium medical devices. Int J Antimicrob Agents 2008, 32(6):481-484.
• [23]Fujimura S, Sato T, Kikuchi T, Zaini J, Gomi K, Watanabe A: Efficacy of clarithromycin plus vancomycin in mice with implant-related infection caused by biofilm-forming Staphylococcus aureus. J Orthop Sci 2009, 14(5):658-661.
• [24]Tateda K, Ishii Y, Kimura S, Horikawa M, Miyairi S, Yamaguchi K: Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery? J Infect Chemother 2007, 13(6):357-367.
• [25]Skindersoe ME, Alhede M, Phipps R, Yang L, Jensen PO, Rasmussen TB, Bjarnsholt T, Tolker-Nielsen T, Hoiby N, Givskov M: Effects of antibiotics on quorum sensing in pseudomonas aeruginosa. Antimicrob Agents Chemother 2008, 52(10):3648-3663.
• [26]Cirioni O, Ghiselli R, Silvestri C, Minardi D, Gabrielli E, Orlando F, Rimini M, Brescini L, Muzzonigro G, Guerrieri M, et al.: Effect of the combination of clarithromycin and amikacin on pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection. J Antimicrob Chemother 2011, 66(6):1318-1323.
• [27]Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, Cirkovic I, Ruzicka F: Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS 2007, 115(8):891-899.
• [28]Stepanović S, Vuković D, Dakić I, Savić B, Švabić-Vlahović M: A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 2000, 40(2):175-179.
• [29]Ruscher C, Lubke-Becker A, Semmler T, Wleklinski CG, Paasch A, Soba A, Stamm I, Kopp P, Wieler LH, Walther B: Widespread rapid emergence of a distinct methicillin- and multidrug-resistant Staphylococcus pseudintermedius (MRSP) genetic lineage in Europe. Vet Microbiol 2010, 144(3–4):340-346.
• [30]Clinical and Laboratory Standards Institute: Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals—Third Edition: Approved Standard M31-A. Wayne, PA, USA: CLSI; 2008.
• [31]Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK, Givskov M, Hoiby N: Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(−/−) mice. Antimicrob Agents Chemother 2007, 51(10):3677-3687.
• [32]Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M: The influence of azithromycin on the biofilm formation of pseudomonas aeruginosa in vitro. Chemotherapy 1996, 42(3):186-191.
• [33]Hudetz D, Ursic Hudetz S, Harris LG, Luginbuhl R, Friederich NF, Landmann R: Weak effect of metal type and ica genes on staphylococcal infection of titanium and stainless steel implants. Clin Microbiol Infect 2008, 14(12):1135-1145.
• [34]Perreten V, Kadlec K, Schwarz S, Gronlund Andersson U, Finn M, Greko C, Moodley A, Kania SA, Frank LA, Bemis DA, et al.: Clonal spread of methicillin-resistant Staphylococcus pseudintermedius in Europe and North America: an international multicentre study. J Antimicrob Chemother 2010, 65(6):1145-1154.